Nantes, France, June 23th, 2010 - VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, announced that its research and development teams have moved into its new facility in Saint-Herblain Nantes, France.This new 3,300 m² (35,520 ft2) facility is dedicated to R&D activities and support functions. The project was initiated at the end of 2008 and integrates all research teams onto the same site, which is adjacent to Vivalis’ existing 1,500 m² (16,150 ft2) cGMP bioproduction facility, completed in 2005... [PDF] Vivalis' Press Release - PDF du communiqué de presse de Vivalis -[...]
...Vivalis at a glance
Vivalis was founded in 1999 with the aim to better understand the extraordinary biological properties of embryonic stem (ES) cells and to use this knowledge for practical applications in human and animal health. ES cells are very unique in that they can self-renew indefinitely in vitro while maintaining a table chromosomal content, and have unlimited regenerative capacity in vivo. Today, the huge therapeutic and industrial potential of ES cells is widely acknowledged but still mostly untapped. Several years of research investments have made of Vivalis a world leader in ES cells. In particular, the company’s distinctive expertise in the field of avian ES cells has led to the development and successful commercialization of its proprietary EB66® platform, a series of documented cells lines derived from chicken and duck ES cells... [PDF] Vivalis at a glance - PDF "l'activité de Vivalis" -
